Understanding the recent increase in ferritin levels in united states dialysis patients: Potential impact of changes in intravenous iron and erythropoiesis- stimulating agent dosing

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 10, 2015, Pages 1814-1821

  Karaboyas, Angelo ^a   Zee, Jarcy ^a   Morgenstern, Hal ^a,b,c   Nolen, Jacqueline G ^d   Hakim, Raymond ^e   Kalantar Zadeh, Kamyar ^f   Zager, Philip ^g   Pisoni, Ronald L ^a   Port, Friedrich K ^a   Robinson, Bruce M ^a,c  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Vifor (International) Inc   (Switzerland)

^e VANDERBILT UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; IRON;

ARTICLE; BLOOD ANALYSIS; CLINICAL EVALUATION; CLINICAL PRACTICE; HEMODIALYSIS; HUMAN; INFORMATION PROCESSING; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; UNITED STATES; AGED; ANEMIA; BLOOD; CARE BUNDLE; DRUG LABELING; FEMALE; HEALTH CARE POLICY; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ADMINISTRATION, INTRAVENOUS; AGED; ANEMIA; DRUG LABELING; FEMALE; FERRITINS; HEALTH POLICY; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; MALE; MIDDLE AGED; PATIENT CARE BUNDLES; PROSPECTIVE STUDIES; RENAL DIALYSIS; UNITED STATES;

EID: 84943786773     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02600315     Document Type: Article

References (26)

1. Centers for Medicare & Medicaid Services (CMS), HHS: Medicare program; end-stage renal disease prospective payment system. Final rule. Fed Regist 75: 49029-49214, 2010
2. U.S. Food and Drug Administration: US FDA drug safety communication: Modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease, 2011. Available at: http://www.fda.gov/drugs/ drugsafety/ucm259639.htm Accessed January 15, 2015
3. FullerDS, Pisoni RL, Bieber BA,Gillespie BW, Robinson BM: The DOPPS Practice Monitor for US dialysis care: trends through December 2011. Am J Kidney Dis 61: 342-346, 2013
4. Fuller DS, Pisoni RL, Bieber BA, Port FK, Robinson BM: The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis 62: 1213-1216, 2013
5. Brunelli SM, Monda KL, Burkart JM, Gitlin M, Neumann PJ, Park GS, Symonian-Silver M, Yue S, Bradbury BD, Rubin RJ: Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS). Am J Kidney Dis 61: 947-956, 2013
6. Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH: Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 37: 564-572, 2001
7. National Kidney Foundation: K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 37[Suppl 1]: S182-S238, 2001
8. National Kidney Foundation: KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. CPG and CPR 3.2. Using iron agents. Am J Kidney Dis 47[Suppl 3]: S1-S146, 2006
9. Kidney Disease; Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int [Suppl 2]: 279-335, 2012
10. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, Szczech L: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 62: 849-859, 2013
11. Coyne DW, Brennan DC: Seeking safe and efficacious anemia management. Semin Dial 22: 590-591, 2009
12. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysisassociated anemia. Kidney Int 35: 712-716, 1989
13. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held PJ: The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study. Kidney Int 57[Suppl 74]: S74-S81, 2000
14. Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA: The Dialysis Outcomes and Practice Patterns Study (DOPPS): Design, data elements, and methodology. Am J Kidney Dis 44[Suppl 2]: 7-15, 2004
15. The Dialysis Outcomes and Practice Patterns Study Practice Monitor. Available at:www.dopps.org/DPM/ AccessedDecember 15, 2014
16. Baron RM, Kenny DA: The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51: 1173-1182, 1986
17. Pearl J: The causal mediation formula-a guide to the assessment of pathways and mechanisms. Prev Sci 13: 426-436, 2012
18. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology: Considerations and challenges in defining optimal iron utilization in hemodialysis. J AmSoc Nephrol 26: 1238- 1247, 2015
19. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19: 141-149, 2004
20. The European Union Clinical Trials Register. Available at: https:// www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/ GB and http://www.kidneyresearchuk.org/pivotal Accessed January 29, 2015
21. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T: Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46: 678-684, 2014
22. Gammella E, Diaz V, Recalcati S, Buratti P, Samaja M, Dey S, Noguchi CT, Gassmann M, Cairo G: Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly. Am J Physiol Regul Integr Comp Physiol 308: R330-R335, 2015
23. Preacher KJ, Kelley K: Effect size measures for mediationmodels: Quantitative strategies for communicating indirect effects. Psychol Methods 16: 93-115, 2011
24. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM: Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 87: 162-168, 2015
25. Rezakhani S, Streja E, Ravel VA, Rhee C, Molnar ZM, KovesdyCP, Mehrotra R, Kalantar-Zadeh K: Longitudinal changes in serum ferritin over 5 years in 134,090 incident dialysis patients. Presented at the American Society of Nephrology, Philadelphia, PA, November 11-16, 2014
26. Centers for Medicare & Medicaid Services ESRD Payment. Available at: http://www.cms.gov/Medicare/Medicare-Feefor- Service-Payment/ESRDpayment/Spotlight.html Accessed December 8, 2014.